By Fineline Cube 
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.
Product Pipeline and Clinical Development
Accropeutics’ product pipeline includes several promising candidates:
- AC-101, an RIPK2 inhibitor developed from Accropeutics’ “regulatory cell death and inflammation”-targeted R&D platform, is being developed to treat inflammatory bowel disease (IBD). It is currently undergoing a Phase Ib study in ulcerative colitis (UC) in China and received approval for trials in the US last December.
- AC-201, a TYK2/JAK1 inhibitor, is nearing the completion of Phase II studies in moderate to severe plaque psoriasis in Australia and China.
- AC-003, a RIPK1 inhibitor, is undergoing Phase Ib studies in acute graft-versus-host disease (aGVHD) in the US and China.
Strategic Focus
The proceeds from this financing round will be dedicated to advancing the clinical development of these and other candidates in Accropeutics’ pipeline, with a focus on addressing significant unmet medical needs in inflammatory and autoimmune diseases.-Fineline Info & Tech